BridgeBio Pharma Inc

Stock Chart, Company Information, and Scan Results

$46.34(as of Jul 29, 1:09 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

BridgeBio Pharma Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$46.34
Ticker SymbolBBIO
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees725
CountyUSA
Market Cap$8,791.5M
EBIDTA-662.6M
10-Day Moving Average46.34
P/E Ratio-13.16
20-Day Moving Average45.46
Forward P/E Ratio0.00
50-Day Moving Average40.92
Earnings per Share-3.56
200-Day Moving Average33.36
Profit Margin-143.55%
RSI61.65
Shares Outstanding189.9M
ATR1.40
52-Week High48.68
Volume2,054,057
52-Week Low21.72
Most Recent Support Level45.27
Book Value-1,638.7M
Most Recent Resistance Level47.05
P/B Ratio-5.36
Upper Keltner48.61
P/S Ratio68.99
Lower Keltner42.31
Debt-to-Equity Ratio48.61
Next Earnings Date08/05/2025
Cash Surplus388.5M
Next Ex-Dividend DateUnknown

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc In Our Stock Scanner

As of Jul 29, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Falling WedgeScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low PB RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.